A Case Report of Dexamethasone Associated Vision Loss in A Young Multiple Myeloma Patient

Dexamethasone is a highly potent glucocorticoid commonly used in the treatment regimens of Multiple Myeloma (MM). This case report describes an acute vision loss developed in a female patient, after starting Bortezomib-Cyclophosphamide-Dexamethasone regimen (VCd) for newly diagnosed MM. Opthalomology evaluation revealed the diagnosis of central serous chorioretinopathy, which was completely resolved after stopping dexamethasone. This case emphasizes the need for close monitoring and optimization of steroid dose in patients with MM and other plasma cell dyscrasias.